Contents

Search


ibudilast

Indications: - methamphetamine withdrawal - may improve vigilance & attention - may diminish brain volume loss in patients with progressive multiple sclerosis [2] - approved in Japan in 1989 for use in bronchial asthma & post-stroke dizziness [2] Dosage: - 20 mg or 50 mg BID Adverse effects: - nausea, diarrhea, abdominal pain - depression (9% vs 3%) - rash - fatigue Mechanism of action: - allegedly targets neuroinflammation [1] - inhibitor factor [2] - macrophage migration inhibitory factor - phosphodiesterase-4 inhibitor - phosphodiesterase-10 inhibitor - toll-like receptor 4 inhibitor

General

heterocyclic compound, 2 rings ketone anti-inflammatory agent

Database Correlations

PUBCHEM cid=3671

References

  1. Birath JB, Briones M, Amaya S et al. Ibudilast may improve attention during early abstinence from methamphetamine. Drug Alcohol Depend 2017 Jun 23; 178:386. PMID: 2870476
  2. Fiore K Anti-Inflammatory Drug May Offer Benefit in Progressive MS - Ibudilast seems to diminish brain volume loss; MedPage Today. October 29, 2017 https://www.medpagetoday.com/MeetingCoverage/ECTRIMS/68865 - Fox RJ et al SPRINT-MS/NN 102 phase II trial of ibudilast in progressive MS: top-line results. ECTRIMS-ACTRIMS 2017; Abstract 278.